Evaluating the Use of Merlin-YAP Dual-label Immunohistochemistry for Predicting Response to TEAD Inhibitor VT3989

Comparing TEAD Palmitoylation Inhibitors with Differential TEAD Selectivity in Combination Efficacy with Targeted Therapies and in Renal Safety

VT3989, a clinical TEAD palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and PI3K/AKT/mTOR pathways